Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score

Scheiner, Bernhard; Pomej, Katharina; M. Kirstein, Martha; Hucke, Florian; Finkelmeier, Fabian; Waidmann, Oliver; Himmelsbach, Vera; Schulze, Kornelius; von Felden, Johann; Fründt, Thorben; Stadler, Marc; Heinzl, Harald; Shmanko, Kateryna; Spahn, Stephan; Radu, Pompilia; Siebenhüner, Alexander; C. Mertens, Joachim; N. Rahbari, Nuh; Kütting, Fabian; Waldschmidt, Dirk‐Thomas; P. Ebert, Matthias; Teufel, Andreas; De Dosso, Sara; J. Pinato, David; Pressiani, Tiziana; Meischl, Tobias; Balcar, Lorenz; Müller, Christian; Mandorfer, Mattias; Reiberger, Thomas; Trauner, Michael; Personeni, Nicola; Rimassa, Lorenza; Bitzer, Michael; Trojan, Jörg; Weinmann, Arndt; Wege, Henning; Dufour, Jean‐François; Peck‐Radosavljevic, Markus; Vogel, Arndt; Pinter, Matthias

doi:10.1016/j.jhep.2021.09.035

Public

Prognosis of patients with hepatocellular carcinoma treated with immunotherapy – development and validation of the CRAFITY score

Published in Journal of Hepatology • Oct 13, 2021

Authors:

Bernhard Scheiner

Katharina Pomej

Martha M. Kirstein

Abstract

BACKGROUND & AIMS: Immunotherapy with atezolizumab plus bevacizumab represents the new standard of care in systemic front-line treatment of hepatocellular carcinoma (HCC). However, biomarkers that predict treatment success and survival remain an unmet need. METHODS: Patients with HCC put on PD-(L)1-...

Subject

Medicine

Internal medicine

Hepatocellular carcinoma

Research Assistant

AI chat, annotations, notes & similar papers

Finding related papers...

Discussions

(0)

No comments yet

Be the first to share your thoughts!